RenovoRx Affirms FY2026 Sales Guidance of $3.000M-$4.000M vs $3.244M Est.
Benzinga Newsdesk 5 months ago
NewsGuidance
RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.000 million-$4.000 million to $3.000 million-$4.000 million vs $3.244 million estimate.
RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.000 million-$4.000 million to $3.000 million-$4.000 million vs $3.244 million estimate.